FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Uveal Melanoma.

Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...

In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...

Becomes the first subcutaneously administered PD-1 inhibitor.

By binding to CTLA4, which is a key negative regulator of T-cell activation, ipilimumab (developed by Medarex in conjunction with Bristol-Myers Squibb) acts to potentiate the immune response ...

Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...

LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations Among 187 patients identified (median follow-up, 22.4 ...

I'm your host Rohit Singh, Assistant Professor at the University of Vermont Cancer Center and today we'll be discussing the article “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus ...